Filing Details

Accession Number:
0001651308-21-000209
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-21 17:37:32
Reporting Period:
2021-10-19
Accepted Time:
2021-10-21 17:37:32
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651308 Beigene Ltd. BGNE Pharmaceutical Preparations (2834) 981209416
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1683913 Jane Huang C/O Mourant Governance Services (Cayman)
94 Solaris Avenue
Camana Bay, Grand Cayman E9 KY1-1108
Cmo, Hematology No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Acquisiton 2021-10-19 1,500 $119.96 1,500 No 4 M Direct
American Depositary Shares Disposition 2021-10-19 200 $362.05 1,300 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 100 $370.14 1,200 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 100 $371.65 1,100 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 400 $373.75 700 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 400 $375.08 300 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 200 $376.36 100 No 4 S Direct
American Depositary Shares Disposition 2021-10-19 100 $377.71 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (Right to Buy) Disposition 2021-10-19 19,500 $0.00 19,500 $9.23
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
250,276 2029-06-04 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Ordinary Shares 145,235 Direct
Footnotes
  1. Each American Depositary Share represents 13 Ordinary Shares.
  2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2020.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.15, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $373.11 to $374.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $374.82 to $375.40, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $375.89 to $376.83, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
  7. The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
  8. These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.